Novartis tried to undermine publicly funded trials of Avastin in AMD, says BMJ
This article was originally published in Scrip
Executive Summary
In the latest round of the sparring over whether Roche's Avastin (bevacizumab) should be used off-label in place of Novartis's more expensive Lucentis (ranibizumab) in wet age-related macular degeneration, the British Medical Journal has published a series of articles suggesting that Novartis hindered UK public clinical trials comparing the two drugs in order to maintain sales of Lucentis.